Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1

Joanne M. LangleyComments to Author , Soren Gantt, Caroline Quach, Julie A. Bettinger, Scott A. Halperin, Jill Mutch, Shelly A. McNeil, Brian J. Ward, Donna MacKinnon-Cameron, Lingyun Ye, Kim Marty, David Scheifele, Erin Brown, Joenel Alcantara, and The Canadian Immunization Research Network
Author affiliations: Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada (J.M. Langley, S.A. Halperin, J. Mutch, S.A. McNeil, D. MacKinnon-Cameron, L. Ye); Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia, Canada (S. Gantt, J.A. Bettinger, K. Marty, D. Scheifele); University of Montreal, Montreal, Quebec, Canada (C. Quach); Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (C. Quach, B.J. Ward); University of Calgary, Calgary, Alberta, Canada (E. Brown, J. Alcantara)

Main Article

Table 1

Characteristics of study participants in trial of MenB-4C vaccine, Canada*

Characteristic Study groups
Total p value
Accelerated Longer interval
Mean age, y (SD) 21.2 (2.9) 20.7 (2.9) 20.6 (2.9) 0.44
Age range, y†
 17–26
 1 –26
 17– 6
Sex, no. (%)
M 18 (30) 19 (31.1) 37 (30.6) 1.0
F
 42 (70)
 42 (68.9)
 84 (69.4)
Body mass index, median
 23
 22.8
 22.9
 0.17
Concurrent health conditions, no. (%)‡ 29 (48.3) 49 (30) 59 (48.8) 1.0
Concomitant medication, no. (%)§ 50 (83.3) 52 (85.2) 102 (84.3) 0.8
Tobacco use, no. (%)
 9 (15)
 8 (13.1)
 17 (14.1)
 0.79
Prior receipt of non-Men B vaccine, no. (%)# 49 (90.7) 46 (90.2) 95 (90.5) 1.0

*The accelerated schedule was MenB-4C vaccine at 0 and 21 days. The longer interval schedule was MenB-4C vaccine at 0 and 60 days. MenB, Neisseria meningitidis serotype B; MenB-4C, 4-component protein-based menB.
†The first day of the birth month used to calculate age for inclusion criteria of 17–25 years of age,
‡The most common medical conditions were asthma, migraine headaches, seasonal allergies, and musculoskeletal complaints.
§The most common concomitant medications were annual influenza vaccine, contraceptive medications, over-the-counter pain and cold preparations, and asthma and allergy medications.
#In Canada, the public health vaccine program includes a monovalent meningococcal C conjugate vaccine at 12 months of age and quadrivalent or monovalent meningococcal C conjugate vaccine in adolescence.

Main Article

1Preliminary results from this study were presented at IDWeek, October 26–30, 2016, New Orleans, LA, USA; and at the Meningitis Research Foundation Conference, November 14–15, 2017, London, England, UK.

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external